Navitoclax
Precursor B-Cell Acute Lymphoblastic Leukemia
Explore 24 assets in Precursor B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Princess Maxima Center for Pediatric Oncology
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05740449CT.gov HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Precursor B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Navitoclax (this asset) | Princess Maxima Center for Pediatric Oncology | P1/2 | CC · 45 |
| Blinatumomab | Amgen | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2/3 | BB |
| Cyclophosphamide | Princess Maxima Center for Pediatric Oncology | P2/3 | BB |
| Cytarabine | Princess Maxima Center for Pediatric Oncology | P2 | B |
| Olverembatinib | First Affiliated Hospital of Zhejiang University | P2 | B |
| Pegaspargase | First Affiliated Hospital of Zhejiang University | P2 | B |
| Methotrexate | First Affiliated Hospital of Zhejiang University | P2 | B |
| Dexasone | Princess Maxima Center for Pediatric Oncology | P2 | B |
+19 more in the Precursor B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Navitoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1/2 | B · 58 |
| T-Lymphoblastic Lymphoma | — | P2 | CCC · 53 |
| Mantle Cell Lymphoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Navitoclax in Precursor B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/navitoclax-precursor-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →